ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025
ALX Oncology (NASDAQ: ALXO) has announced a webcast event scheduled for May 20, 2025, focusing on ALX2004, their novel antibody-drug conjugate (ADC). The event will showcase ALX2004's mechanism of action, preclinical data, and clinical development strategy following FDA's IND clearance earlier this year.
ALX2004, developed in-house using the company's proprietary topoisomerase I inhibitor payload platform, is designed to target EGFR-expressing tumors. The presentation will feature key executives including CEO Jason Lettmann, CMO Alan Sandler, and VP of Antibody Technologies Marija Vrljic, who will discuss planned clinical progress and updates.
ALX Oncology (NASDAQ: ALXO) ha annunciato un evento webcast programmato per il 20 maggio 2025, incentrato su ALX2004, il loro nuovo coniugato anticorpo-farmaco (ADC). L'evento presenterà il meccanismo d'azione di ALX2004, i dati preclinici e la strategia di sviluppo clinico dopo l'approvazione IND da parte della FDA avvenuta all'inizio di quest'anno.
ALX2004, sviluppato internamente utilizzando la piattaforma proprietaria di inibitori della topoisomerasi I dell'azienda, è progettato per colpire tumori che esprimono EGFR. La presentazione vedrà la partecipazione di dirigenti chiave, tra cui il CEO Jason Lettmann, il CMO Alan Sandler e il VP delle Tecnologie Anticorpali Marija Vrljic, che discuteranno i progressi clinici pianificati e gli aggiornamenti.
ALX Oncology (NASDAQ: ALXO) ha anunciado un evento webcast programado para el 20 de mayo de 2025, centrado en ALX2004, su nuevo conjugado anticuerpo-fármaco (ADC). El evento mostrará el mecanismo de acción de ALX2004, datos preclínicos y la estrategia de desarrollo clínico tras la aprobación IND de la FDA a principios de este año.
ALX2004, desarrollado internamente utilizando la plataforma propietaria de inhibidores de la topoisomerasa I de la compañía, está diseñado para atacar tumores que expresan EGFR. La presentación contará con ejecutivos clave, incluyendo al CEO Jason Lettmann, al CMO Alan Sandler y a la VP de Tecnologías de Anticuerpos Marija Vrljic, quienes discutirán el progreso clínico planificado y las actualizaciones.
ALX Oncology (NASDAQ: ALXO)는 2025년 5월 20일에 예정된 웹캐스트 이벤트를 발표했으며, 이번 행사는 그들의 새로운 항체-약물 접합체(ADC)인 ALX2004에 초점을 맞춥니다. 이번 이벤트에서는 ALX2004의 작용 기전, 전임상 데이터 및 올해 초 FDA의 IND 승인 이후 임상 개발 전략을 소개할 예정입니다.
ALX2004는 회사의 독자적인 토포이소머라제 I 억제제 탑재 플랫폼을 이용해 자체 개발되었으며, EGFR 발현 종양을 표적으로 설계되었습니다. 발표에는 CEO Jason Lettmann, CMO Alan Sandler, 항체 기술 부문 부사장 Marija Vrljic 등 주요 경영진이 참여하여 예정된 임상 진행 상황과 최신 정보를 공유할 것입니다.
ALX Oncology (NASDAQ : ALXO) a annoncé un événement webcast prévu pour le 20 mai 2025, axé sur ALX2004, leur nouveau conjugué anticorps-médicament (ADC). L'événement présentera le mécanisme d'action d'ALX2004, les données précliniques et la stratégie de développement clinique suite à l'autorisation IND de la FDA plus tôt cette année.
ALX2004, développé en interne grâce à la plateforme propriétaire de charge utile inhibitrice de topoisomérase I de la société, est conçu pour cibler les tumeurs exprimant l'EGFR. La présentation réunira des cadres clés, dont le PDG Jason Lettmann, le directeur médical Alan Sandler et la vice-présidente des technologies des anticorps Marija Vrljic, qui discuteront des progrès cliniques prévus et des mises à jour.
ALX Oncology (NASDAQ: ALXO) hat eine Webcast-Veranstaltung für den 20. Mai 2025 angekündigt, die sich auf ALX2004, ihren neuartigen Antikörper-Wirkstoff-Konjugat (ADC), konzentriert. Die Veranstaltung wird den Wirkmechanismus von ALX2004, präklinische Daten und die klinische Entwicklungsstrategie nach der IND-Freigabe durch die FDA Anfang dieses Jahres vorstellen.
ALX2004 wurde intern unter Verwendung der firmeneigenen Topoisomerase-I-Inhibitor-Nutzlastplattform entwickelt und ist darauf ausgelegt, EGFR-exprimierende Tumore zu bekämpfen. Die Präsentation wird von wichtigen Führungskräften wie CEO Jason Lettmann, CMO Alan Sandler und VP für Antikörpertechnologien Marija Vrljic begleitet, die den geplanten klinischen Fortschritt und Updates besprechen werden.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that it will host a webcast event on May 20, 2025, to provide an update on ALX2004, the Company’s potentially best- and first-in-class investigational antibody-drug conjugate (ADC). The webcast will highlight the novel mechanism of action, preclinical data and clinical development strategy for ALX2004 following clearance of the Investigational New Drug application from the U.S. Food and Drug Administration earlier this year.
ALX2004 was fully designed and developed in-house by ALX Oncology scientists. By leveraging the Company’s proprietary, highly differentiated topoisomerase I inhibitor payload platform, ALX2004 optimizes ADC-based mechanisms of anti-tumor activity and is designed to improve outcomes in patients with EGFR-expressing tumors.
ALX Oncology leadership Jason Lettmann, Chief Executive Officer, Alan Sandler, Chief Medical Officer and Marija Vrljic, Vice President of Antibody Technologies, will discuss planned clinical progress and updates for ALX2004 during the virtual webcast event.
ALX2004 Webcast Information
The virtual event will be webcast live and a replay will be available after the event by visiting the "Investors" section of ALX Oncology’s website and selecting "Events and Presentations."
Date & Time: Tuesday, May 20, 2025, 8:00 a.m. PT/11:00 a.m. ET
Webcast Access: https://edge.media-server.com/mmc/p/ohnn53h5
About ALX Oncology
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at www.alxoncology.com and on LinkedIn @ALX Oncology.
Investor Relations Contact:
Elhan Webb, CFA, IR Consultant
ewebb@alxoncology.com
Media Contact:
Audra Friis, Sam Brown Healthcare Communications
audrafriis@sambrown.com
(917) 519-9577
FAQ
What is ALX2004 and how does it work?
When is ALX Oncology (ALXO) hosting its R&D webcast for ALX2004?
What is the current development status of ALX2004?
Who will be presenting at the ALX Oncology webcast event?
